Thu.Aug 11, 2022

article thumbnail

FundamentalVR rakes in $20M for its VR, haptics platform

MedCity News

FundamentalVR, a startup that sells virtual reality and haptic software for medical simulation, recently closed a $20 million Series B funding round. The company will use the funds to invest in Fundamental Surgery, its platform that recreate the sights, sounds and sensations that surgeons experience during medical procedures.

Medical 114
article thumbnail

Pharma Distribution: Carving New Ground

Pharmaceutical Commerce

Pharmaceutical distribution today is anything but monolithic. While companies in this space are grappling with issues ranging from inflation and supply chain disruption to workforce scarcity and DSCSA implementation, there’s still plenty of room for smaller players to stake out part of the terrain to call their own.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Employees want help with their health benefits, survey finds

MedCity News

Many employed Americans misunderstand their health insurance plans, and 72% want someone to just tell them what the best plan is for their specific needs, the survey found.

Insurance 113
article thumbnail

Ultrasound Sticker for 48 Hours of Imaging

Medgadget

Engineers at MIT have created an ultrasound patch that can provide long-term ultrasound imaging of internal organs and structures. The device contains a rigid piezoelectric probe array and uses an underlying layer of elastomer-covered hydrogel in lieu of the gel applied to the skin during conventional ultrasound procedures. At just the size of a postage stamp, the ultrasound patch is highly portable and less expensive than conventional ultrasound technologies.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Meet the 7 startups Mayo Clinic just welcomed to its AI accelerator

MedCity News

Mayo Clinic recently welcomed seven more healthcare startups to its accelerator program. In exchange for an equity position in each startup, Mayo Clinic gives young digital health companies the opportunity to refine their AI models using its deidentified data sets and subject matter experts.

article thumbnail

DNA-Based Nanorobot Interacts with Live Cells

Medgadget

Researchers at INSERM (Institut national de la santé et de la recherche médicale) in France, and collaborators, have developed a DNA-based nanorobot called the Nano-winch. The tiny creation is made using DNA molecules and a “DNA Origami” approach. The tiny robot is so small that it can land on a cell surface and interact with ‘mechanoreceptors’ that the cell uses to sense mechanical forces acting on it.

Medical 107

More Trending

article thumbnail

Regions On Rise: Life Sciences Across US

Pharmaceutical Commerce

Exploring the competitive and unique offerings in three of the US’s lower-cost economic development regions—and how success in these areas has been boosted by COVID.

article thumbnail

Abridge scores $12.5M, launches AI-powered medical notetaking tool for doctors

MedCity News

Abridge, a medical conversation AI startup, recently closed an oversubscribed $12.5 million Series A funding round. The company also launched a new app for physicians that listens to visits and creates a near-instant summary that adheres to their prototypical note structure.

Doctors 107
article thumbnail

Samsung Biologics recognised for sustainable growth

European Pharmaceutical Review

The Frost & Sullivan Institute stated that it is proud to present Samsung Biologics with the 2022 Enlightened Growth Leadership Award for not only demonstrating growth excellence but also social responsibility. In announcing the award, the Institute asserted that it “believes that all organisations must either create or become part of a solution that addresses threats to humanity,” highlighting Samsung’s strong environmental, social and governance (ESG) and sustainability initiatives the rea

article thumbnail

After RNA therapy falls short in the eye, ProQR Therapeutics pivots to liver, CNS

MedCity News

RNA therapies developer ProQR Therapeutics is eying a future without ophthalmology. After receiving European Medicines Agency feedback for its lead program for a rare eye disorder, the biotech has decided to find a strategic partner for all of its eye drug assets and apply its RNA technology to other therapeutic areas.

Medicine 103
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

GSK, Sanofi and Haleon ‘facing billions of dollars in Zantac liability’

pharmaphorum

GSK, its consumer health spin-off Haleon and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug pulled from the market in 2020 after it was linked to cases of cancer. That’s the conclusion of analysts at Morgan Stanley, Deutsche Bank and UBS, who have all issued research notes drawing attention to the issue, which has remained largely off the radar since sales of Zantac (ranitidine) were halted.

article thumbnail

340B entities face increased challenges in a shifting regulatory and enforcement landscape

MedCity News

Concerns about who qualifies under the 340B Program, how drugs can be dispensed to patients, and how much entities will be reimbursed may significantly impact the operation of the 340B Program as Congress intended. This evolving landscape poses challenges to all stakeholders.

Patients 103
article thumbnail

Powering Rapid Cognitive Analysis with AI

Impetus Digital

Dr. Tom Sawyer , CFO at Cognetivity Neurosciences , sat down with me to discuss the benefits of AI-driven dementia detection technology for patients, health care providers, and clinical research. He also shared his predictions for the future of digital health and his tips for biotech startups looking to raise capital and grow their company. Here is a sneak peek of our conversation: Q: One of the core areas or fundamental products, if you will, that Cognetivity specializes in, is the initial pi

article thumbnail

Viome Life Sciences launches at-home oral/throat cancer test for consumers

MedCity News

The saliva-based test has been found to have 95% specificity and 90% sensitivity. Consumers can purchase it online and have it shipped to their house.

106
106
article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

article thumbnail

Expanding Subscription Offers in RightFind Offers SME Organizations More Options and Flexibility

Copyright Clearance Center

The post Expanding Subscription Offers in RightFind Offers SME Organizations More Options and Flexibility appeared first on Copyright Clearance Center.

98
article thumbnail

Patients will bear the steepest consequences of proposed cuts to home health

MedCity News

In the current market where inflation and the costs of healthcare continue to rise, there’s […].

Patients 114
article thumbnail

How Pharmacogenomics may finally realise its promise

pharmaphorum

More than 60 percent of all American adults take prescription drugs , amounting to approximately 131 million individuals. These drugs have been rigorously tested by regulatory bodies around the world before they’re made available to ensure they work as labelled, but despite that, adverse events crop up. In 2016, the estimated annual cost of drug-related morbidity and mortality resulting from non-optimised medication therapy was $528.4 billion in the United States alone.

article thumbnail

As pharma M&A ramps up, U.S. execs are bullish on more deals

PharmaVoice

What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.

Pharma 96
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Trio of therapies reduces risk of death in patients with severe COVID-19

European Pharmaceutical Review

Hospitalised patients on high-flow oxygen for severe COVID-19 pneumonia were nearly 50 percent less likely to die when treated with antiviral remdesivir in combination with steroid dexamethasone and baricitinib, according to research from Rutgers Ernest Mario School of Pharmacy in the US. The research was published in the Canadian Journal of Infectious Diseases and Medical Microbiology in July. .

article thumbnail

Key blood clotting protein could be ‘warning light’ for COVID-19 cases

PharmaTimes

University of Aberdeen team suggest results indicate that protein PAI-1 could be an early indicator of severe COVID-19

92
article thumbnail

Increase in dry powder inhalers could lead to decreases in greenhouse gas emissions

Pharmaceutical Technology

Asthma is a chronic respiratory condition that, according to GlobalData’s Epidemiology Database, affects approximately 14% of the UK population, and almost 88 million people in the seven major markets worldwide (US, UK, France, Germany, Italy, Spain, and Japan). Common symptoms include wheezing, shortness of breath, and limited airflow, which can vary in severity.

Leads 64
article thumbnail

Novartis’ Pluvicto gets first European approval in GB

pharmaphorum

Novartis has secured its first approval in Europe for prostate cancer radioligand therapy Pluvicto, getting a green light from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Pluvicto (lutetium (177Lu) vipivotide tetraxetan) has been cleared for adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with androgen receptor inhibitors and taxane-based chemotherapy or not medically suitable for taxane drugs.

article thumbnail

The New Clinical Trial Supply Chain: Resilient, Flexible, and Patient-Centric

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.

article thumbnail

Gemini enters business combination deal with Disc Medicine

Pharmaceutical Technology

Gemini Therapeutics has signed a definitive agreement to merge with Disc Medicine in an all-stock deal to create a clinical-stage biopharmaceutical company. To back the merger, Disc raised funds worth $53.5m from a group of healthcare investors led by Access Biotechnology and also include OrbiMed, Atlas Venture and 5AM Ventures among others. The merged company is expected to be named Disc Medicine, which will have corporate headquarters in Watertown, Massachusetts, US.

article thumbnail

3rd TIGIT Axis Therapies Summit

pharmaphorum

The 3rd TIGIT Axis Therapies Summit returns to unite large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in the solid tumor, blood cancer and non-oncology setting. Covering deciphering the mechanistic intricacies underlying TIGIT axis signaling , defining combination partners that improve efficacy and strengthen TIGIT targeted pipelines , exploring novel drug designs

article thumbnail

Medicines Discovery Catapult and Zeiss join forces

PharmaTimes

Partnership will focus on driving the application of microscopy in drug discovery

article thumbnail

Genetic Counselors Insight: Growing Popularity of At Home Testing

InCrowd

With the growing popularity of at-home testing for genetics, we asked Genetic Counselors their thoughts on at-home testing and its efficacy. We first asked – What do you think about patients doing at home testing? For example, Everlywell, LetsGetChecked, 23andMe etc? On a scale of 1 to 7, with 7 being strongly agree, most questions averaged in the middle ground of 3.17-5.75 with the strongest opinions being on accuracy of the tests and the importance of consulting with a healthcare provide

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Spain’s pharma industry IT recruitment activity rises 18.3% in July 2022

Pharmaceutical Technology

Spain’s pharma industry registered an 18.3% rise in IT hiring activity in July 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The industry’s overall hiring increased by 1.22% in July 2022 when compared with June 2022. Out of the pharma industry’s total hiring activity, IT jobs claimed a 9.33% share in July 2022, recording a decrease of 0.91% over the last three-month average share.

article thumbnail

Abecma hits the mark in earlier-stage multiple myeloma

pharmaphorum

Bristol-Myers Squibb is on course to move its BCMA-targeting CAR-T therapy further up the treatment pathway in multiple myeloma, after reporting that it met its objectives in a phase 3 trial. 2seventy bio-partnered Abecma (idecabtagene vicleucel) is already approved as a fourth-line or later therapy for the blood cancer, and the KarMMa-3 study is designed to support second or third-line treatment with the CAR-T.

Safety 52
article thumbnail

US pharma industry IT recruitment activity drops 5.1% in July 2022

Pharmaceutical Technology

The US’s pharma industry registered a 5.1% drop in IT hiring activity in July 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The industry’s overall hiring is decreased by 4.42% in July 2022 when compared with June 2022. Out of the pharma industry’s total hiring activity, IT jobs claimed a 1.92% share in July 2022, recording an increase of 0.06% over the last three-month average share.

article thumbnail

Digital health firm Biofourmis adds another $20m to its funding pot

pharmaphorum

One of the digital health sector’s latest unicorn companies – Biofourmis – has upscaled its recent fourth round financing, adding $20 million to the $300 million it raised in April. The top-up comes from Intel Capital, the strategic investment arm of chipmaker Intel, and has been announced alongside two new additions to Biofourmis’ board of directors.

article thumbnail

Clinical Supply Strategies for CROs

When a CRO is bidding on a project where clinical supplies will be one of the aspects to manage on behalf of the client via a partner, leveraging the expertise of a chosen clinical supply partner can be a valuable resource in demonstrating the CRO’s understanding of and ability to deliver upon critical drug-supply related aspects of the project, and ability to hit key milestones such as FPI for their client.